menu
    • menu

    Company profile for Towa International

    NEW Drugs in Dev: 20
    Towa Pharmaceutical-PSE
    News
    Towa Receives Manufacturing & Marketing Approval for Generic Drug

    16 Feb 2026

    // PRESS RELEASE

    FY2025(3rd quarter) Supplementary Material of Financial Results

    13 Feb 2026

    // PRESS RELEASE

    Consolidated Financial Results for the 9 Months Ended December

    13 Feb 2026

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Towa Pharmaceutical

    Contact Supplier

    Website

    CPhI Milan

    Booth #5D33

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    https://www.youtube.com/embed/prL_A0I4ZVQ

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Towa International works to research, develop, manufacture, and market, generic and value-added medicines to patients around the world.

    Related CompaniesRelated Companies

    About

    Towa International is the global hub of Towa Pharmaceutical, a leading generic company in Japan. Based in Barcelona, it focuses on the research, development, manufacturing, marketing, and distribution of generic and value-added medicines. It operates through four complementary business units: Towa US (Breckenridge Pharmaceutical), Towa EU (Italy, Spain, and Portugal), Towa 2B (worldwide), and the new CDMO unit. With nearly 1,000 employees globally, Towa International continues to grow its presence in the generics market. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Towa InternationalSpain_new Flag
    Country
    Country
    Spain
    Address
    Address
    C/ Sant Martí 75-79 08107 Martorelles (Barcelona)
    Telephone
    Telephone
    +34 936411000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://towainternational.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/towainternational/
    youtube
    YouTube
    https://www.youtube.com/@towainternational
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI Milan

    Booth #5D33

    envelop Contact Supplier

    CPhI Milan

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/towa-pharmaceutical-party-content-2847.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/towa-pharmaceutical-party-content-68909.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Every year, the US Food and Drug Administration (FDA) publishes the user fee amounts it will collect from manufacturers of pharmaceuticals, generic drugs, biosimilars and medical devices in the coming financial year. The fee for fiscal year 2025 under the Generic Drug User Fee Act (GDUFA) was published on July 31, 2024.The GDUFA, established in 2012, authorizes FDA to assess and collect fees from drug manufacturers to expedite the delivery of safe, high-quality, and affordable generic drugs to the American public.The FDA’s facility payments list under GDUFA reveals that as of November 14, 2024, 1,397 facilities had paid their registration fees for financial year 2025. Of these facilities, 707 or 50.6 percent are active pharmaceutical ingredients (API) facilities, 405 or 29 percent are finished dosage forms (FDF) facilities, 69 (4.9 percent) are facilities that produce both APIs and FDFs, and 216 (15.5 percent) are contract manufacturing services (CMO) sites.Teva Pharmaceuticals, with 29 facility registrations, led the list of companies, followed by Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories. Fiscal year Facility Registrations 2016 1,425 2017 1,442 2018 1,269 2019 1,286 2020 1,300 2021 1,340 2022 1,385 2023 1,394 2024 1,447 2025 1,397  Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available)India continues to lead with 396 facilities, US and China follow India maintains its dominance in total facility registrations with the FDA, registering 396 facilities for FY2025. This includes 214 API facilities, 135 FDF facilities, 21 facilities engaged in both API and FDF activities, and 26 CMO facilities.The United States holds the second position with 328 facilities, while China strengthened its third position with 197 facilities.With 214 API facilities, India continues to have the largest share of API manufacturing sites, outmatching the combined total of China (128) and the US (83), which together account for 211 facilities. Among European manufacturers, Italy leads with 59 API manufacturing sites, followed by Spain (30) and Germany (25).The US has maintained its lead in FDF facilities with 143 sites, followed closely by India with 135 sites and China with 45 sites. Country API FDF Both CMO Total India 214 135 21 26 396 US 83 143 13 89 328 China 128 45 12 12 197 Italy 59 3 2 19 83 Germany 25 4 1 15 45 Spain 30 9 1 4 44 Canada 7 17   13 37 Taiwan 9 6 5 4 24 Switzerland 15 4   4 23 France 16     6 22 Japan 18   1   19 United Kingdom 12 1   2 15 Mexico 9 1   1 11 Ireland 5 5   1 11   Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) GDUFA III user fee rates increase across categories for FY25The GDUFA, which was reauthorized on September 30, 2022 (as GDUFA III), continues with provisions that will last until September 30, 2027. In July 2024, the FDA published updated user fee rates for FY2025.The facility fees have seen increases across all categories. API facility fees increased by 3 percent for domestic sites (to US$ 41,580) and 2 percent for foreign sites (to US$ 56,580). FDF facility fees rose by 5 percent for both domestic (to US$ 231,952) and foreign sites (to US$ 246,952). CMO facility fees increased by 5 percent for domestic sites (to US$ 55,668) and 4 percent for foreign sites (to US$ 70,668).Additionally, the fee for large-, medium- and small-sized drug applicants has increased by over 9 percent, compared to the 7 percent increase seen in 2023. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) China leads new facility registrations as FDA records 41 new units in FY25Out of the total 1,397 facilities registered for FY2025, 41 were new registrations (going by Facility FDA Establishment Identifier numbers). China led the way with 13 new facilities, followed closely by India with 11 new facilities, while the US secured the third position with eight new facilities.The new registrations included 15 API facilities, 13 CMO facilities, 12 FDF facilities, and one facility engaged in both API and FDF activities. Chinese companies dominated the new FDF registrations with six facilities: Chengdu Shuode Pharma, Chengdu Suncadia Medicine, Cipla (Jiangsu), GE Healthcare (Shanghai), Luoxin Aurovitas Pharma (Chengdu), and Zhejiang Xianju Pharma.India added two new FDF facilities through Eugia Steriles and Zydus Pharma. Malaysia registered two FDF facilities through Novugen Pharma and Novugen Oncology, while Turkey’s Insud Pharma subsidiary Exeltis and US’ RK Pharma registered one FDF facility each.The 13 new CMO facilities included, Acme Generics, Emcure, Esjay Pharma, Fordoz Pharma, Fourrts Laboratories, Laboratoires KABS, PharmaMax, Quality Packaging Specialists International, Ritsa Pharma, Shanghai Aucyun Pharma, Sichuan Huiyu Pharma, Taejoon Pharm, and Tubilux Pharma.In the API category, the 15 new registrations included Acharya Chemicals, Hainan Poly Pharma, CBL Patras, EUROAPI, Hybio Pharma, Medilux Laboratories, Metrochem API, Purolite, Chengdu Easton Biopharma, Sionc Pharma, Smithfield Bioscience, Xttrium Laboratories, Zhejiang Hengkang Pharma, Moehs Iberica and Shilpa Pharma. Armstrong Pharmaceuticals registered the sole facility for both APIs and FDFs.So far, 92 facilities have not renewed their registration. Among these was a facility owned by Sandoz subsidiary Eon Labs in Wilson, North Carolina (US), which is permanently closed. In fact, the geographical distribution of non-renewals shows that 30 facilities were from the US, while India and China accounted for 14 and nine non-renewals respectively. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) Our viewThe FY 2025 GDUFA facility registration data indicates a continued strong presence of Indian manufacturers in the US generic drug market, particularly in API production. However, China's leadership in new facility registrations, especially in FDF manufacturing, suggests that the global generic drug supply chain landscape may evolve considerably in the coming years. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 15969

    https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities

    #PharmaFlow by PHARMACOMPASS
    21 Nov 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Towa Receives Manufacturing & Marketing Approval for Generic Drug
    Towa Receives Manufacturing & Marketing Approval for Generic Drug

    16 Feb 2026

    // PRESS RELEASE

    https://www.towayakuhin.co.jp/english/assets/release260216.pdf

    PRESS RELEASE
    16 Feb 2026
    Share Share
    FY2025(3rd quarter) Supplementary Material of Financial Results
    FY2025(3rd quarter) Supplementary Material of Financial Results

    13 Feb 2026

    // PRESS RELEASE

    https://www.towayakuhin.co.jp/english/assets/slide70c.pdf

    PRESS RELEASE
    13 Feb 2026
    Share Share
    Consolidated Financial Results for the 9 Months Ended December
    Consolidated Financial Results for the 9 Months Ended December

    13 Feb 2026

    // PRESS RELEASE

    https://www.towayakuhin.co.jp/english/assets/result70c.pdf

    PRESS RELEASE
    13 Feb 2026
    Share Share
    Brand–Generic Collaboration to Secure Off-patent Drug Supply
    Brand–Generic Collaboration to Secure Off-patent Drug Supply

    21 Jan 2026

    // PRESS RELEASE

    https://www.towayakuhin.co.jp/english/assets/release260121_2.pdf

    PRESS RELEASE
    21 Jan 2026
    Share Share
    Towa Pharma Integrated Report 2025 has been released
    Towa Pharma Integrated Report 2025 has been released

    22 Dec 2025

    // PRESS RELEASE

    https://www.towayakuhin.co.jp/english/assets/2025en.pdf

    PRESS RELEASE
    22 Dec 2025
    Share Share
    Towa FY2025(2nd Q) Supplementary Material of Financial Results
    Towa FY2025(2nd Q) Supplementary Material of Financial Results

    10 Nov 2025

    // PRESS RELEASE

    https://www.towayakuhin.co.jp/english/assets/slide70b.pdf

    PRESS RELEASE
    10 Nov 2025
    Share Share

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search